Related Experiment Video
Updated: Dec 27, 2025

Recapitulation of an Ion Channel IV Curve Using Frequency Components
Published on: February 8, 2011
Differential Inhibitory Actions of Multitargeted Tyrosine Kinase Inhibitors on Different Ionic Current Types in
Wei-Ting Chang1,2,3, Ping-Yen Liu1,4, Kaisen Lee5
1Institute of Clinical Medicine, College of Medicine, National Cheng Kung University, Tainan 70101, Taiwan.
Abstract:
Lapatinib (LAP) and sorafenib (SOR) are multitargeted tyrosine kinase inhibitors (TKIs) with antineoplastic properties. In clinical observations, LAP and SOR may contribute to QTc prolongation, but the detailed mechanism for this has been largely unexplored. In this study, we investigated whether LAP and SOR affect the activities of membrane ion channels. Using a small animal model and primary cardiomyocytes, we studied the impact of LAP and SOR on Na+ and K+ currents. We found that LAP-induced QTc prolongation in mice was reversed by isoproterenol. LAP or SOR suppressed the amplitude of the slowly activating delayed-rectifier K+ current (IK(S)) in H9c2 cells in a time- and concentration-dependent fashion. The LAP-mediated inhibition of IK(S) was reversed by adding isoproterenol or meclofenamic acid, but not by adding diazoxide. The steady-state activation curve of IK(S) during exposure to LAP or SOR was shifted toward a less negative potential, with no change in the gating charge required to activate the current. LAP shortened the recovery from IK(S) deactivation. As rapid repetitive stimuli, the IK(S) amplitude decreased; however; the LAP-induced inhibition of IK(S) remained effective. LAP or SOR alone also suppressed inwardly rectifying K+ and voltage-gated Na+ current in neonatal rat ventricular myocytes. The inhibition of ionic currents during exposure to TKIs could be an important mechanism underlying changes in QTc intervals.
Insights
Lapatinib (LAP) and sorafenib (SOR), tyrosine kinase inhibitors (TKIs), prolong QTc intervals by suppressing cardiac ion channel activity, particularly the slowly activating delayed-rectifier K+ current (IK(S)). This mechanism underlies their cardiotoxicity.
Area of Science:
- Cardiology
- Pharmacology
- Molecular Biology
Background:
- Lapatinib (LAP) and sorafenib (SOR) are multitargeted tyrosine kinase inhibitors (TKIs) with antineoplastic properties.
- Clinical observations suggest LAP and SOR may cause QTc prolongation, but the underlying mechanisms remain largely uninvestigated.
Purpose of the Study:
- To investigate the effects of LAP and SOR on membrane ion channel activities.
- To elucidate the detailed mechanism by which LAP and SOR induce QTc prolongation.
Main Methods:
- Utilized a small animal model and primary cardiomyocytes to study the impact of LAP and SOR on Na+ and K+ currents.
- Examined the effects of LAP and SOR on the slowly activating delayed-rectifier K+ current (IK(S)) in H9c2 cells.
- Investigated the influence of LAP and SOR on inwardly rectifying K+ and voltage-gated Na+ currents in neonatal rat ventricular myocytes.
Main Results:
- LAP-induced QTc prolongation in mice was reversible by isoproterenol.
- LAP and SOR suppressed the amplitude of IK(S) in a time- and concentration-dependent manner, shifting its activation curve towards less negative potentials.
- LAP and SOR also inhibited inwardly rectifying K+ and voltage-gated Na+ currents in cardiomyocytes.
Conclusions:
- LAP and SOR suppress key cardiac ion currents, including IK(S), contributing to QTc interval prolongation.
- The inhibition of these ionic currents represents a significant mechanism underlying the cardiotoxicity associated with these TKIs.
More Related Videos
07:42Contractions of Human-iPSC-derived Cardiomyocyte Syncytia Measured with a Ca-sensitive Fluorescent Dye in Temperature-controlled 384-well Plates
Published on: October 18, 2018
08:11Voltage-Dependent Potassium Current Recording on H9c2 Cardiomyocytes via the Whole-Cell Patch-Clamp Technique
Published on: November 11, 2022
Related Concept Videos
Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers
Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
Heart Failure Drugs: Inotropic Agents
Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers
Depolarizing Blockers: Mechanism of Action
Succinylcholine is the most commonly used depolarizing blocker. Chemically, it constitutes two molecules of acetylcholine joined together by an acetate methyl group. They act on the receptors in the same way as acetylcholine. Because...